| 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence. | |
| | |
MedLine Citation:
|
PMID: 19039558 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The aim of this study was to evaluate the diagnostic accuracy of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) for staging/restaging, evaluating the treatment response, and screening of recurrence in patients with malignant lymphoma (ML) during long-term follow-up, and to compare that with computer tomography (CT)/magnetic resonance imaging (MRI). METHODS: The study was conducted in 59 ML patients who underwent whole-body 18F-FDG-PET examinations three times or more from October 1998 to August 2006. The location of the lesions in the patients with positive findings on 18F-FDG-PET and/or the corresponding CT/MRI was classified into supradiaphragmatic (n = 10), infradiaphragmatic (n = 7), and extranodal sites (n = 20), and the findings were compared on a site basis according to the gold standard, which consisted of all clinical information available, including follow-up results. RESULTS: A total of 156 18F-FDG-PET examinations for which the corresponding CT/MRI images were also available were evaluated, and a total of 305 sites showed positive findings on 18F-FDG-PET and/or CT/MRI. Concordant positive findings were obtained in 76% for staging/restaging, 34% for evaluation of the treatment response, and 50% for screening of recurrence. The accuracy of 18F-FDG-PET versus CT/MRI was 92% versus 84% (P = 0.06) for staging/restaging, 84% versus 50% (P < 0.05) for the evaluation of the treatment response, and 83% versus 72% (P = 0.21) for the screening of recurrence. At pathologic sites with discrepant findings between 18F-FDG-PET and CT/MRI (n = 122), the frequency of accurate diagnosis by 18F-FDG-PET (76%) was higher than that by CT/MRI (24%), especially for the evaluation of the treatment response. CONCLUSIONS: 18F-FDG-PET is expected to play a significant role in the management of ML patients even after effective treatment is initiated. |
| | |
Authors:
|
Kayako Isohashi; Mitsuaki Tatsumi; Ichiro Higuchi; Atsuo Inoue; Kazuya Nakajo; Jun Ishikawa; Eku Shimosegawa; Yuzuru Kanakura; Hironobu Nakamura; Jun Hatazawa |
Related Documents
:
|
18619228 - Reticuloendothelium malignancy: current role of imaging. 12442918 - Positron emission tomography for the staging of hodgkin's lymphoma--increasing the body... 17411738 - Imaging to optimally stage lung cancer: conventional modalities and pet/ct. 9829578 - Planar coincidence scintigraphy and pet in staging malignant melanoma. 18654908 - Inter- and intrafractional movement of the tumour in extracranial stereotactic radiothe... 12698638 - Radiographic assessment of airway tumors. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-11-28 |
Journal Detail:
|
Title: Annals of nuclear medicine Volume: 22 ISSN: 0914-7187 ISO Abbreviation: Ann Nucl Med Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-11-28 Completed Date: 2009-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8913398 Medline TA: Ann Nucl Med Country: Japan |
Other Details:
|
Languages: eng Pagination: 795-802 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Female Fluorodeoxyglucose F18 / diagnostic use* Follow-Up Studies Humans Longitudinal Studies Lymphoma / radionuclide imaging*, therapy* Male Neoplasm Recurrence, Local / prevention & control*, radionuclide imaging* Neoplasm Staging / methods Positron-Emission Tomography / methods* Prognosis Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.
Next Document: Incidence and characteristics of uterine leiomyomas with FDG uptake.